User:Mr. Ibrahem/Natalizumab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | alpha-4 integrin |
| Clinical data | |
| Trade names | Tysabri, Antegren, others |
| Other names | AN100226M |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605006 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous infusion |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Elimination half-life | 11 ± 4 days |
| Chemical and physical data | |
| Molar mass | 149 kg/mol |
  (what is this?) (verify) | |
Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis (MS) and Crohn's disease (CD).[3] For MS it is used for clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.[3] For CD it is used when other treatments are not effective.[3] It is given by gradual injection into a vein every 4 weeks.[4]
Common side effects include urinary tract infection, throat inflammation, headache, dizziness, nausea, joint pain and tiredness.[4] Other side effects may include progressive multifocal leukoencephalopathy (PML), herpes encephalitis, liver problems, anaphylaxis, low platelets, and infection.[3] It is a monoclonal antibody which attaches to a protein called α4β1 integrin on white blood cells, decreasing inflammation.[4]
Natalizumab was approved for medical use in the United States in 2004 and Europe in 2006.[5][4] In the United Kingdom it costs the NHS about £1,100 per dose as of 2021.[6] In the United States this amount costs about 7,800 USD.[7]
References[edit]
- ^ a b "Natalizumab (Tysabri) Use During Pregnancy". Drugs.com. 24 September 2019. Archived from the original on 23 November 2020. Retrieved 4 May 2020.
- ^ "Tysabri 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 14 November 2019. Archived from the original on 22 October 2020. Retrieved 4 May 2020.
- ^ a b c d e f "Tysabri- natalizumab injection". DailyMed. 12 August 2019. Archived from the original on 27 March 2020. Retrieved 4 May 2020.
- ^ a b c d e "Tysabri EPAR". European Medicines Agency (EMA). Archived from the original on 6 August 2020. Retrieved 4 May 2020. Text was copied from this source, which is © EMA [1995-2020]. Reuse is authorised, provided the source is acknowledged.
- ^ "Natalizumab Monograph for Professionals". Drugs.com. Archived from the original on 6 February 2017. Retrieved 12 November 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 905. ISBN 978-0857114105.
- ^ "Tysabri Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 January 2021. Retrieved 12 November 2021.